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Abstract: 
 
Thioredoxin reductase (TrxR) is a target for cancer therapy and the anticancer mechanism 
of cisplatin involves TrxR inhibition. We hypothesize that the anticancer drug nedaplatin (NDP), 
an analogue of cisplatin and a second-generation platinum complex, also targets TrxR. 
Furthermore, we investigate whether the therapeutic efficacy of NDP can be enhanced by 
simultaneous modulation of 1) TrxR, via NDP, and 2) glutathione (GSH), via the GSH synthesis 
inhibitor buthionine sulfoximine (BSO). Mice bearing ascitic hepatoma 22 (H22) cells were 
treated with NDP alone or NDP plus BSO. TrxR activity of H22 cells was inhibited by NDP in a 
dose-dependent manner. A high correlation between the inhibition of TrxR activity at 6 h and the 
inhibition of ascitic fluid volume at 72 h was established (r = 0.978, p < 0.01). As an adaptive 
response, the viable ascitic cancer cells after NDP treatment displayed an enlarged cell 
phenotype, assembled with several-fold more antioxidant enzymes and GSH-predominant non-
protein free thiols. This adaptive response was largely eliminated when BSO was co-
administered with NDP, leading to the decimation of the H22 cell population without 
enhancing renal toxicity, since at this dose, NDP did not inhibit renal TrxR activity. In 
conclusion, the pharmacological effect of NDP involves TrxR inhibition, and the adaptive 
response of NDP-treated ascitic H22 cells can be efficiently counteracted by BSO. Simultaneous 
modulation of TrxR and GSH on ascitic H22 cells using NDP plus BSO greatly enhances 
therapeutic efficacy as compared with the single modulation of TrxR using NDP alone. 
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Abbreviations: ASK1, apoptosis signal-regulated kinase-1; BSA, bovine serumalbumin; BSO, 
buthionine sulfoximine; BUN, urea nitrogen; CDNB, 1-chloro-2,4-dinitrobenzene; Cr, 
creatinine; DTNB, 5,5′-dithiobis (2-nitrobenzotic acid); GPx, glutathione peroxidase; GR, 
glutathione reductase; GRAN#, granulocytes; GSH, reduced glutathione; GST, glutathione S-
transferase; H22, ascitic hepatoma 22 cells; HGB, hemoglobin; i.p., intraperitoneally; LYM#, 
lymphocytes; NADPH, nicotinamide-adenine dinucleotide phosphate; NDP, nedaplatin; NPFT, 
nonprotein free thiol; NSCLC, non-small-cell lung carcinoma; SCLC, small cell lung carcinoma; 
PLT, platelets; RBC, red blood cells; RNR, ribonucleotide reductase; SecTRAPs, 
seleniumcompromised TrxR-derived apoptotic proteins; SOD, superoxide dismutase; Trx, 
thioredoxin; TrxR, thioredoxin reductase; WBC, white blood cells. 
 
Introduction 
 
The thioredoxin system, comprising selenocysteine-containing thioredoxin reductase (TrxR), 
thioredoxin (Trx) and nicotinamide-adenine dinucleotide phosphate (NADPH), participates in a 
broad range of cellular functions, such as the redox control of apoptosis and proliferation-
associated signaling and regulatory proteins (Arnér, 2009). TrxR is over-expressed in many 
cancer cells, where it incites pro-survival effects and enhances tumor development and resistance 
to therapeutic modalities (Gromer et al., 2004, Nguyen et al., 2006). TrxR1 knockdown Lewis 
lung carcinoma cells showed a dramatic reduction in tumor progression and metastasis (Yoo et 
al., 2006). Several commonly used anticancer drugs including cyclophosphamide, ifosfamide, 
cisplatin and oxaliplatin (Wang et al., 2007, Wang et al., 2008, Witte et al., 2005, Zhang et al., 
2008) inactivate TrxR activity, thus adding to the cytotoxic potential of these agents. The 
selenocysteine-dependent TrxR enzyme has emerged as an important molecular target for 
anticancer drug development (Cai et al., 2012b, Pennington et al., 2007, Tonissen and Di 
Trapani, 2009). 
 
Glutathione (GSH), a predominant nonprotein free thiol (NPFT) molecule found in cells at 
millimolar concentrations, plays a crucial role in cell defense mechanisms by acting as an 
antioxidant or conjugating with toxic electrophiles (Davis et al., 2001, Lu et al., 2007). The 
sensitivity of cancer cell lines to chemotherapy is inversely correlated with their GSH content 
(Andringa et al., 2006, Dai et al., 1999, Meurette et al., 2005, Wu et al., 2004). A positive 
correlation between elevation of intracellular GSH levels and resistance to platinum or alkylating 
agents has been established (Biroccio et al., 2004, Dai et al., 1999, Troyano et al., 2001). In 
cultured MCF-7 cells, GSH depletion by buthionine sulfoximine (BSO), an inhibitor of GSH 
synthesis, markedly potentiates the cytotoxicity of arsenic trioxide, a TrxR inhibitor. 
Accordingly, the simultaneous modulation of TrxR and GSH is considered as a powerful strategy 
for cancer therapy (Lu et al., 2007). 
 
Cis-diammine-glycolate-O,O′-platinum II (nedaplatin, referred to as NDP) is a second-
generation platinum complex developed and approved in Japan (Ogawa, 1996, Sasaki et al., 
1991). As an analogue of cisplatin, NDP has a novel ring structure in which glycolate is bound to 
platinum by a bidentate ligand (Alberto et al., 2009). NDP is ten-fold more water soluble than 
cisplatin (Vermorken, 2001). NDP causes significantly less nausea, vomiting and nephrotoxicity 
than cisplatin and thus can be given without hydration (Desoize and Madoulet, 2002, Kawai et 
al., 2005, Ogawa, 1996, Sasaki et al., 1991, Vermorken, 2001). The dose-limiting toxicity of 
NDP is myelosuppression, in particular thrombocytopenia (Desoize and Madoulet, 2002, Kawai 
et al., 2005, Ogawa, 1996, Sasaki et al., 1991, Vermorken, 2001). The anticancer mechanism of 
NDP involves the formation of reactive platinum complexes that bind to nucleophilic groups in 
DNA, leading to intrastrand and interstrand DNA cross-links and cellular apoptosis (Alberto et 
al., 2009). Preclinical and clinical studies have demonstrated that nedaplatin has anticancer 
activities equivalent to that of cisplatin (Desoize and Madoulet, 2002, Ogawa, 1996, Sasaki et al., 
1991, Vermorken, 2001). Since its approval in 1995, NDP has been used in the treatment 
of testicular tumors, small cell lung carcinoma (SCLC), non-small-cell lung carcinoma 
(NSCLC), esophageal cancer, bladder cancer, ovarian and cervical cancers, and head and neck 
tumors (Desoize and Madoulet, 2002, Kawai et al., 2005, Koshiyama et al., 2005, Monk et al., 
1998, Ogawa, 1996, Vermorken, 2001). 
 
We have reported previously that cisplatin inactivated TrxR activity in ascitic hepatoma 22 
(H22) cells in mice (Zhang et al., 2008). The current work investigated whether NDP targets 
TrxR of cancer cells in vivo. We found that the TrxR activity of ascitic H22 cells in mice could 
be inhibited by NDP in dose-dependent fashion, and the inhibition of TrxR activity was highly 
correlated with the inhibition of ascitic fluid volume. As an adaptive response, the viable ascitic 
H22 cells after NDP treatment displayed an enlarged cell phenotype, equipped with 2 to 5-fold 
more of various antioxidant enzymes and GSH-predominant NPFT. This adaptive response could 
be almost fully counteracted by BSO, greatly enhancing the cytotoxicity of NDP without 
generating renal toxicity, since at the dose used, NDP did not inhibit renal TrxR activity. 
 
Materials and methods 
 
Chemicals and drugs 
 
BSO, NADPH, HEPES, insulin, 5,5′-dithiobis (2-nitrobenzotic acid) (DTNB), Trx (E. coli), 
guanidine hydrochloride, reduced GSH, bovine serum albumin (BSA), 1-chloro-2,4-
dinitrobenzene (CDNB), RNase A and propidium iodide were all purchased from Sigma (St. 
Louis, MO, USA). NDP was purchased from Nanjing Tung Chit Pharmaceutical Co., Ltd., PR 
China. Other chemicals were of the highest grade available. 
 
Animals 
 
Healthy male Kunming mice (body weight 20–22 g) and their diet were purchased from 
Shanghai SLAC Laboratory Animal Co. Ltd., PR China. The mice were housed in plastic cages 
in a room with controlled temperature (22 ± 1 °C) and humidity (50 ± 10%) and 12 h light/dark 
cycle. The mice were allowed to obtain food and water ad libitum. 
 
Tumor cell inoculation 
 
H22 murine carcinoma cells were obtained from the Cell Bank of the Chinese Academy of 
Sciences (Shanghai, China). In brief, viable cells in ascitic fluid were counted using trypan 
blue dye exclusion. The concentration of cells in ascitic fluid was adjusted to 100 × 106 cells/mL 
using saline, then 0.2 mL was intraperitoneally (i.p.) injected into the peritoneal cavity of mice; 
this procedure was carried out once weekly. 
 
Animal treatments 
 
All experiments involving mice were performed in strict compliance with the ethical guidelines 
issued by the Anhui Agricultural University. 
 
In the first set of experiments, to investigate the dose effect of NDP on cellular antioxidant 
parameters and ascitic fluid volume, 48 mice were randomly divided into 4 groups of 12. 
Seventy-two hours after cell inoculation at a level of 20 million cells per mouse, group I was i.p. 
injected with saline as control, and groups II–IV were i.p. injected with NDP at the doses of 15, 
25 and 35 mg/kg, respectively. Six mice in each group were euthanized by cervical dislocation at 
6 h, and the rest were euthanized at 72 h after NDP treatment. Ascitic fluid was collected directly 
or with the aid of a known volume of ice cold saline if necessary and centrifuged to obtain H22 
cells. 
 
In the second set of experiments, to observe the effects of NDP on cell cycle, proliferation, 
morphology and cellular antioxidant inclusion, 24 mice were randomly divided into 2 groups of 
12. Seventy-two hours after cell inoculation at a level of 20 million cells per mouse, group I was 
i.p. injected with saline as control, and group II was i.p. injected with NDP at a dose of 
25 mg/kg. Six mice in each group were euthanized by cervical dislocation at 6 h, and the rest 
were euthanized at 72 h after NDP treatment. Ascitic fluid was collected directly or with the aid 
of a known volume of ice cold saline if necessary and centrifuged to obtain H22 cells. 
 
In the third set of experiments, to inspect the potential toxicity of BSO and its effects on NPFT 
levels as well as H22 cell proliferation, twenty-four mice were randomly divided into 2 groups of 
12. Seventy-two hours after cell inoculation at a level of 20 million cells per mouse, group I was 
i.p. injected with saline as control, and group II was i.p. injected with BSO at a dose of 
500 mg/kg. Six mice in each group were euthanized by cervical dislocation at 6 h, and the rest 
were euthanized at 72 h after BSO treatment. Ascitic fluid samples were collected to obtain H22 
cells, and renal tissues were dissected. 
 
In the fourth set of experiments, to elucidate the effect of BSO on NDP cytotoxicity, 36 mice 
were randomly divided into 3 groups of 12. Seventy-two hours after cell inoculation at a level of 
20 million cells per mouse, group I was i.p. injected with saline as control, groups II and III were 
i.p. injected with NDP at a dose of 25 mg/kg, and group III was simultaneously i.p. injected with 
BSO at a dose of 500 mg/kg. Six mice in each group were euthanized by cervical dislocation at 
6 h, and the rest were euthanized at 72 h after NDP treatment. Ascitic fluid was collected directly 
or with the aid of a known volume of ice cold saline if necessary and centrifuged to obtain H22 
cells. 
 
In the fifth set of experiments, to address the impact of BSO on NDP toxicity, 42 mice were 
randomly divided into 3 groups of 14. Group I was i.p. injected with saline as control, groups II 
and III were i.p. injected with NDP at a dose of 25 mg/kg, and group III was simultaneously i.p. 
injected with BSO at a dose of 500 mg/kg. Six mice in each group were euthanized by cervical 
dislocation at 6 h after NDP treatment to dissect kidney tissues; the rest were euthanized at 72 h 
after NDP treatment to obtain blood samples and kidney tissues. 
 
Sample preparation and biochemical parameters 
 
H22 cells were homogenized in ice cold 0.15 M PBS (pH 7.2) with 1 mM EDTANa2 by 
ultrasonication for 30 min in an ice bath. Kidney tissues were homogenized in a glass 
homogenizer with the above-mentioned PBS (1:9, w/v). Blood samples collected in EDTA-
coated tubes were subjected to hematological evaluation including white blood cells (WBC), red 
blood cells (RBC), hemoglobin (HGB), platelets (PLT), lymphocytes (LYM#), and granulocytes 
(GRAN#) by using an auto analyzer. Blood samples collected in EDTA-coated tubes were 
centrifuged to obtain plasma for measuring urea nitrogen (BUN) and creatinine (Cr) levels by 
using commercial kits. 
 
For the NPFT assay, immediately after homogenization, an aliquot of homogenate was taken out 
to mix with trichloroacetic acid (20%, w/v), at the volume ratio of 10:1. This procedure has been 
confirmed to be able to precipitate all proteins in the homogenate and make GSH in the 
homogenate stable at 4 °C for at least 2 h (Wang et al., 2008). The trichloroacetic acid-treated 
homogenate was centrifuged at 10,000 g and 4 °C for 5 min. Within 2 h after centrifugation, the 
supernatant was mixed with DTNB (20 mg/mL in 0.2 M PBS, pH 8.0) and absorbance was read 
at 412 nm (Wang et al., 2008). Protein levels were determined by the Bradford dye-binding assay 
with BSA as standard. Since the cell dimension increased substantially and cellular soluble 
protein level accordingly increased after NDP treatment, activity per million cells rather than per 
mass of protein was more appropriate for use as a basis for normalization. Thus NPFT level was 
expressed as nmol GSH/million cells (Barranco et al., 1990, Hunter et al., 1987, Lee et al., 
1989). 
 
For antioxidant enzyme assays, the remaining homogenate was centrifuged at 15,000 g and 4 °C 
for 15 min. The supernatants were used for activity determinations, including TrxR, glutathione 
peroxidase (GPx), glutathione S-transferase (GST), glutathione reductase (GR) and superoxide 
dismutase (SOD). 
 
TrxR activity assay 
 
TrxR activity was measured based on the method of Holmgren and Björnstedt (1995) with some 
modifications. A stock mixture was composed of HEPES buffer (1.0 M, pH 7.6), NADPH 
(40 mg/mL), EDTA (0.2 M) and insulin (10 mg/mL) in the volume ratio of 5:1:1:12.5. In a 96-
well plate, 7 μL stock mixture, 3 μL Trx (2 mg/mL), 40 μL HEPES (50 mM, pH 7.6) and 20 μL 
sample (with 20–30 μg protein) were added to each well. The enzymatic reaction was maintained 
at 37 °C for 20 min, and then terminated by adding 240 μL stop solution (6 M guanidine 
hydrochloride, 0.2 mg/mL DTNB, 0.2 M Tris, pH 8.0). Each sample contained a non-enzymatic 
reaction as the control. The non-enzymatic reaction included all components except Trx, which 
was substituted by the same volume of saline. The 96-well plates were read at 412 nm. The 
absorbance of the control was subtracted from the absorbance of the sample. A background 
control, which was the subtraction of absorbance with and without Trx in the absence of tissue 
homogenate, was further subtracted from all samples. TrxR activity unit was defined as nmol of 
NADPH oxidized/min and TrxR activity was expressed as U/million cells. 
 
Other antioxidant enzyme assays 
 
GPx was assayed by the method of Rotruck et al. (1973). Units of GPx activity were calculated 
in terms of μmols of GSH oxidized/min/million cells. GST activity was chemically determined 
by using 1-chloro-2,4-dinitrobenzene (CDNB). Units of GST activity were calculated in terms of 
nmol CDNB changed/min/million cells (Habig et al., 1974). GR activity was assessed by the 
method of Carlberg and Mannervik (Carlberg and Mannervik, 1985); units of GR activity were 
calculated in terms of nmols of NADPH oxidized/min, and GR activity was expressed as 
U/million cells. SOD activity was assayed by using the system of xanthine–xanthine oxidase 
and nitroblue tetrazolium. Units of SOD activity were defined as inhibition of 50% nitroblue 
tetrazolium reduction rate/million cells (Sun et al., 1988). 
 
Cell cycle analysis 
 
H22 cells (5 × 106) were washed twice with PBS and fixed in 70% ice cold ethanol at − 20 °C 
until analysis. The fixed cells were then washed twice with PBS to remove ethanol, incubated 
with 100 μL 1 mg/mL of RNase A at 37 °C for 30 min. Then, 400 μL 50 μg/mL of propidium 
iodide was added to the incubated cells for another 30 min at 4 °C in the dark, with gentle 
shakes. Subsequently, cell cycle phase distribution of nuclear DNA was assayed by flow 
cytometry (FACS Calibur) (Wang et al., 2008). The fluorescence detector was equipped with 
488 nm argon laser light source and 623 nm band pass filter (linear scale) using Cell Quest 
software (Becton Dickinson). A total of 10,000 events were collected and the analysis of the 
flow cytometric data was performed with ModFit software. For each sample, data were acquired 
through two gates, FSC versus SSC and FL2W versus FL2A, to reduce debris and other 
contamination (Wang et al., 2008). 
 
Cell morphology and histopathological observation 
 
Cells were stained with hematoxylin and eosin (H&E) and observed under an optical 
microscope. Kidneys tissues were fixed in 10% neutral buffered formalin solution and embedded 
into molten paraffin wax. Tissue sections of 5 μm thickness were stained with H&E and 
observed under an optical microscope by a pathology expert who was blind to the treatments. 
 
Statistical analysis 
 
Data are presented as mean ± SEM. The differences between groups were evaluated by one way 
ANOVA post hoc Tukey's or Dunnett's multiple comparison tests using GraphPad Software 
(Prism version 5, San Diego, California, USA). A p value of less than 0.05 was considered 
statistically significant. During ANOVA analysis, when Bartlett's test for equal variances showed 
that the variances were significantly different (p < 0.05), the differences between groups were 
evaluated by Dunnett's multiple comparison test. Otherwise, the differences between groups 
were evaluated using Tukey's multiple comparison tests. 
 
Results 
 
Dose effect of NDP on TrxR and ascitic fluid volume 
 
After a bolus dose of NDP (15, 25 or 35 mg/kg) was administered, at 6 h, TrxR activity 
significantly decreased in a dose-dependent manner, by 31%, 49% and 77%, respectively, in 
comparison with the control (Fig. 1A). However, NPFT level and the activities of other 
antioxidant enzymes (GR, GPx, GST and SOD) had no significant variation. At 72 h, ascitic 
fluid volume dose-dependently decreased by 39%, 56% and 71%, compared with the control 
(Fig. 1B). The TrxR inhibition at 6 h was highly correlated with the inhibition of ascitic fluid 
production at 72 h (r = 0.978 and p < 0.01, Fig. 1C). 
 
 
Figure 1. Dose effect of NDP on TrxR activity and ascitic fluid volume. Mice were i.p. injected with either saline or 
NDP at 15, 25 or 35 mg/kg. Half of the mice in each group were euthanized at 6 h, and the rest were euthanized at 
72 h. (A) Antioxidant parameters at 6 h. The basal NPFT level was 1.6 nmol/million cells. The basal activities of 
TrxR, GR, GPx, GST and SOD were 0.18 U/million cells, 3.3 U/million cells, 7.0 U/million cells, 3.2 U/million 
cells and 20.1 U/million cells, respectively. (B) Volume of ascitic fluid at 72 h. (C) The correlation between ascitic 
fluid volume and TrxR activity. 
 
Effects of NDP on cell cycle, proliferation, morphology and antioxidant parameters 
 
NDP treatment at the dose of 25 mg/kg for 72 h caused cell cycle arrest at G2/M phase (Fig. 2A). 
Such cells displayed an enlarged phenotype (Fig. 2B), appeared to proliferate rather slowly 
(Fig. 3A), and possessed approximately 3 times as much soluble protein as compared with the 
control (Fig. 3B). Since soluble protein itself was a variable, it was not appropriate to use it as a 
basis for normalization. We thus used per million cells as a normalization basis for antioxidant 
parameters in the present study. Accordingly, TrxR activity and NPFT level in the enlarged cells 
were increased 3 and 5-fold relative to the control, respectively (Figs. 3C, D). 
 
Figure 2. (A) Effect of NDP on cell cycle distribution. (B) Effect of NDP on cellular morphology (H&E, × 200). 
Mice were i.p. injected with saline or NDP 25 mg/kg. Half of the mice in each group were euthanized at 6 h, and the 
rest were euthanized at 72 h. 
 
 
Figure 3. Effects of NDP on cell proliferation and cellular antioxidant inclusion. Mice were i.p. injected with saline 
or NDP 25 mg/kg. Half of the mice in each group were euthanized at 6 h, and the rest were euthanized at 72 h. (A) 
H22 cell number. (B) Soluble protein. (C) TrxR activity. (D) NPFT level. 
 
Impacts of BSO on NPFT levels and TrxR activity of H22 cells and renal tissues 
 
BSO treatment at the dose of 500 mg/kg for 6 h and 72 h did not alter TrxR activity in H22 cells 
and renal tissues (data not shown). As expected, it significantly suppressed NPFT levels in H22 
cells and renal tissues by the magnitudes of 60% to 70% at either 6 h or 72 h. The BSO treatment 
neither suppressed H22 cell proliferation (data not shown) nor generated perceived toxic 
symptoms including growth suppression in the tested mice. Therefore, the BSO level used 
generated a specific effect of suppressing NPFT levels without initiating cytotoxicity and host 
toxicity. 
 
Impact of BSO on NDP cytotoxicity 
 
Consistent with the above results (Fig. 1A), at 6 h, 25 mg/kg NDP alone significantly suppressed 
TrxR activity by 50% (Fig. 4A) and had no significant impact on NPFT level (Fig. 4B). The co-
administration of BSO did not enhance TrxR activity inhibition as compared to treatment with 
NDP alone (Fig. 4A), but NDP in combination with BSO resulted in significant inhibition of 
both TrxR activity and NPFT level at 6 h (Figs. 4A, B). 
 
 
Figure 4. Impact of BSO on the effect of NDP. Mice were i.p. injected with either saline, 25 mg/kg NDP or 
25 mg/kg NDP plus 500 mg/kg BSO. Half of the mice in each group were euthanized at 6 h, and the rest were 
euthanized at 72 h. (A) TrxR activity at 6 h. (B) NPFT level at 6 h. (C) Effect of BSO on NDP-induced morphology 
enlargement at 72 h (H&E, × 200). 
 
 
Figure 5. Impact of BSO on the effect of NDP. Mice were i.p. injected with either saline, 25 mg/kg NDP or 
25 mg/kg NDP plus 500 mg/kg BSO and were euthanized at 72 h. (A) Soluble protein. (B) Cell number. (C) Cell 
cycle distribution. (D) Antioxidant parameters. The basal NPFT level was 1.5 nmol/million cells. The basal 
activities of TrxR, GST, SOD, GR and GPx were 0.16 U/million cells, 2.9 U/million cells, 21.1 U/million cells, 
3.0 U/million cells and 4.8 U/million cells, respectively. 
 
Consistent with the above observations (Fig. 2, Fig. 3), at 72 h, 25 mg/kg NDP alone caused 
enlargement of cellular volume (Fig. 4C), elevation of soluble protein level (Fig. 5A), 
proliferation inhibition (Fig. 5B), and cell cycle arrest at G2/M phase (Fig. 5C). The co-
administration of BSO fully prevented NDP-induced cell enlargement and protein elevation 
(Figs. 4C, 5A), powerfully enhanced the cytotoxic potential of NDP (Fig. 5B), and shifted cell 
cycle arrest to G0/G1 phase (Fig. 5C). On the basis of per million cells, TrxR activity in NDP-
treated enlarged cells was increased 2.5-fold relative to the control. In contrast, NDP and BSO 
co-treatment decreased TrxR activity by 73% (Fig. 5D). Furthermore, the NPFT level in NDP-
treated cells was increased 3-fold relative to the control, while NPFT level in NDP and BSO co-
treated cells remained close to the control (Fig. 5D). Similarly, other antioxidant enzymes 
increased after treatment with NDP alone, and were suppressed to the control level by BSO, 
except for GPx (Fig. 5D). On the other hand, mice were able to tolerate very well both the 
NDP monotherapy treatment and the combination of BSO and NDP; no perceived toxic 
symptoms were observed during the time frame of the experiment. 
 
Impact of BSO on hematological and renal toxicities of NDP 
 
At 6 h, 25 mg/kg NDP alone did not significantly inhibit renal TrxR activity and alter renal 
NPFT level as compared with the control (Figs. 6A, B). The co-administration of BSO 
powerfully suppressed renal NPFT level (Fig. 6B), and, unlike the profile seen in H22 cells, BSO 
noticeably did not simultaneously generate significant inhibition of both renal TrxR activity and 
renal NPFT levels at 6 h (Figs. 6A, B). 
 
 
Figure 6. Toxicological investigations of the addition of BSO to NDP treatment. Mice were i.p. injected with either 
saline, 25 mg/kg NDP, or 25 mg/kg NDP plus 500 mg/kg BSO. Six mice in each group were euthanized at 6 h, and 
the rest were euthanized at 72 h after NDP treatment. (A) Renal NPFT levels at 6 h. (B) Renal TrxR activity at 6 h. 
(C) Gain in body weight. (D) Histopathological observation of kidney at 72 h (H&E, × 200). (E) Hematological and 
plasma biochemical parameters at 72 h. 
 
As shown in Fig. 6C, mice in the control group grew daily, whereas 25 mg/kg NDP alone 
significantly suppressed the gain of body weight, indicating a toxic response. However, the co-
administration of BSO did not enhance the growth suppression compared to treatment with NDP 
alone. At 72 h, neither NDP alone nor the combination of NDP and BSO altered renal structures 
(Fig. 6D), hematological parameters, or plasma BUN and Cr levels (Fig. 6E). 
 
Discussion 
 
As an electrophile, NDP should be able to react with nucleophiles. Mammalian TrxR has a 
redox-active site (Cys496/Sec497) within the C‐terminal tetrapeptide motif (Gladyshev et al., 
1996). The pKα value of Sec497 is 5.2 (Nordberg and Arnér, 2001), making Sec497 in the TrxR 
molecule present in the form of –Se− at physiological pH. Given that –Se− possesses a stronger 
nucleophilicity and lower pKa value compared with Cys496, TrxR has the propensity to be 
attacked by electrophiles, so it is conceivable that TrxR acts as a molecular target for 
NDP. Inactivation of TrxR by NDP may impede reduction of oxidized Trx and 
induce apoptosis via activating apoptosis signal-regulated kinase-1 (ASK1) (Saitoh et al., 1998). 
Since selenium compromised TrxR-derived apoptotic proteins (SecTRAPs) could act as potent 
killers via inducing apoptotic cell death (Anestål and Arnér, 2003, Anestål et al., 2008, Cai et al., 
2012a), NDP-modified TrxR may further add to the cytotoxic potential of NDP. In the present 
study, at 6 h after NDP treatment, TrxR activity in ascitic H22 cells was inhibited (Fig. 1A), 
while GSH-predominant NPFT and other antioxidant enzymes had no significant changes 
(p all > 0.05, Fig. 1A). NDP caused dose-dependent inhibition of TrxR activity at 6 h (Fig. 1A) 
and dose-dependent reduction of ascitic fluid volume at 72 h (Fig. 1B); moreover, the former 
was well correlated with the latter in a positive linear pattern (r = 0.978, Fig. 1C). These results 
provide in vivo evidence that the pharmacological effect of NDP is associated with the inhibition 
of TrxR activity. As to the selection of cancer cell line in vivo, one of the purposes of this study 
is the demonstration that BSO is able to eliminate NDP-induced drug-resistance. Establishing a 
NDP-resistant cell model in vivo is more likely to succeed using a hepatoma cell line, since 
hepatocellular carcinoma is largely refractory to most chemotherapeutic agents (Zhu, 2006). As 
expected, hepatoma 22 (H22) cells subjected to NDP treatment at a pharmacological dose 
exhibited a drug-resistant phenotype with a prominent feature of enlarged cells equipped with an 
enhanced antioxidant arsenal. These profiles could be demonstrated owing to the likelihood that 
intact cells could be more readily isolated from ascitic fluid. Based on this model, we clearly 
demonstrated that BSO eliminated NDP-induced resistance. Protein levels went up at 72 h after 
25 mg/kg NDP treatment (Fig. 3B) because the cells became much bigger (Fig. 2B). G2 phase 
prior to cell division has two prominent features; one is cell growth, another is massive syntheses 
of protein and RNA (Alberts et al., 2008). G2/M arrest was able to induce morphological 
enlargement of human leukemia HL-60 cells (Hsu et al., 2012). In the present experimental 
model, we observed that NDP-induced G2/M arrest caused not only morphological enlargement 
of H22 cells, but also the accumulation of both protein and RNA (Fig. 3B and Supplementary 
Fig. 1D). Since protein was a variable, the tested biological parameters were not normalized on a 
per milligram protein basis; rather they were normalized on the basis of per million cells. Such a 
normalization method has yet been commonly employed (Barranco et al., 1990, Hunter et al., 
1987, Lee et al., 1989). If TrxR activity was normalized to protein content, 25 mg/kg NDP still 
shows TrxR inhibition by about 50% at 6 h (Fig. 3C), because cell volume was not obviously 
altered (Fig. 2B) and protein levels remained the same as the control (Fig. 3B). However, if TrxR 
activity was normalized to protein content, the TrxR activity was almost the same as the control 
at 72 h, no longer exhibiting the 3-fold increase as seen in Fig. 3C, where TrxR was normalized 
to cell counts. Overall, the TrxR activity at 72 h indicates that NDP does not provide long-term 
inhibition of TrxR activity, i.e. TrxR activity is able to recover back to normal levels on the basis 
of protein amounts or increases to a level significantly higher than normal level on the basis of 
cell counts, provided that cells become bigger. Such a seemingly peculiar phenomenon, referred 
to as temporal inactivation of TrxR activity, is actually not unprecedented in animal studies; in 
fact, this adaptive response in tumor and normal tissues in mice has been well demonstrated. For 
example, TrxR activity can recover back to normal levels at 48–72 h after being significantly 
inhibited by cyclophosphamide, ifosfamide and cisplatin at 4–6 h post administration of these 
drugs at pharmacological levels (Wang et al., 2007, Wang et al., 2008, Zhang and Lu, 
2007, Zhang et al., 2008). In this regard, the present results obtained using NDP are quite 
consistent with the findings of previous studies of mechanistically similar chemotherapeutic 
drugs in mice. Resistance to chemotherapy severely limits its effectiveness (Gottesman and 
Pastan, 1988). The survival of cancer cells after attack by chemotherapeutic drugs may lead to 
the emergence of drug resistance (Stordal and Davey, 2007). At 72 h after 25 mg/kg NDP 
treatment, the proliferation of H22 cells was fully inhibited relative to the cell numbers counted 
at 6 h (290 versus 293 million), whereas H22 cells without NDP treatment proliferated from 
about 300 million at 6 h to roughly 1800 million at 72 h (Fig. 3A). The NDP-generated 
proliferation-compromised viable cells displayed an enlarged morphology (Fig. 2B). 
Accordingly, NPFT levels and activities of a number of antioxidant enzymes substantially 
increased, on the basis of the same amount of cells (Figs. 3C, D, 5D). This expanded antioxidant 
arsenal, as an adaptive response, may help the ascitic H22 cells increase their resistance to 
further drug treatments. Additionally, we used qRT-PCR and western blot methods to 
characterize the gene and protein expression of TrxR1, and the results achieved are consistent 
with our previous finding of TrxR activity, namely, that NDP at 72 h increased TrxR 
activity via elevating the mRNA and protein of TrxR1 (Supplementary Fig. 1). 
 
GSH, a major component of NPFT, plays a crucial role in cell defense mechanisms by acting as 
an antioxidant and conjugating with toxic electrophiles (Davis et al., 2001, Lu et al., 2007). The 
GSH system, comprising NADPH, GSH and GR coupled with glutaredoxins, provides electrons 
to ribonucleotide reductase (RNR) for DNA synthesis (Holmgren, 1989, Lu et al., 2007). GSH 
also participates in providing electrons to GPxs for scavenging hydrogen peroxide (Brigelius-
Flohé and Kipp, 2009, Steinbrenner and Sies, 2009). The Trx system, composed of NADPH, Trx 
and TrxR, is a crucial electron donor system to RNR for DNA synthesis (Holmgren, 1989, Lu et 
al., 2007). Trx also provides electrons to peroxiredoxin for removing hydrogen peroxide (Hall et 
al., 2011, Thamsen et al., 2011). Therefore, compared to TrxR inhibition alone, the inhibition of 
both the Trx and GSH systems attenuates the detoxification of electrophilic xenobiotics and 
enhances DNA synthesis inhibition and oxidative stress. Hence, the simultaneous inhibition of 
both the Trx and GSH systems is a more powerful strategy for cancer control, given that the host 
could be tolerant to the co-treatment of TrxR and GSH synthesis inhibitors. In cultured cancer 
cells, GSH depletion by BSO potentiates the cytotoxicity of arsenic trioxide, a TrxR inhibitor 
(Lu et al., 2007). In the present study, we showed BSO per se neither had cytotoxicity nor caused 
host toxicity except that it significantly suppressed NPFT levels in H22 cells and renal tissues. 
However, BSO effectively prevented NDP-induced enlargement of cellular morphology 
(Fig. 4C), as well as the elevation of antioxidant arsenal (Fig. 5D). The combination of BSO and 
NDP was more cytotoxic than NDP alone to ascitic H22 cells since the combination treatment 
decimated the cell population to less than 30 million, whereas viable cells in treated with NDP 
alone still remained at a level of roughly 300 million (Fig. 5B), being equipped with increased 
antioxidant arsenal as compared with the cells in the combination treatment (Fig. 5D). It is worth 
noting that mice had no apparent difficulties tolerating treatment with either NDP alone or the 
combination of BSO and NDP, no symptoms of toxicity were observed during the experimental 
period. Therefore, herein we have provided in vivo evidence that simultaneous modulation of 
TrxR and GSH is indeed more effective in coping with cancer cells than single modulation of 
TrxR, without an increase in host toxicity. Moreover, an in vitro experiment using human oral 
squamous cell carcinoma cell line Tca8113 was performed. As shown in Supplementary Fig. 2, 
at 6 h we found NDP inhibited TrxR activity and BSO suppressed NPFT levels, both in a dose-
associated fashion. Furthermore, at 18 h, the combination of NDP and BSO enhanced 
cytotoxicity compared to NDP alone, whereas BSO itself did not cause cell death. 
 
BSO not only inhibits GSH synthesis in cancer cells, it also suppresses GSH levels of normal 
tissues. Ifosfamide and cisplatin not only inhibit tumor TrxR activity, they also efficiently 
suppress renal TrxR activity (Zhang and Lu, 2007, Zhang et al., 2008). Although the 
simultaneous modulation of TrxR and GSH appears to be a powerful strategy for cancer therapy, 
the combination of BSO with either ifosfamide or cisplatin has an obvious drawback, because 
kidney tissue cannot escape from the simultaneous modulation. Indeed, either ifosfamide- or 
cisplatin-generated nephrotoxicity could be largely aggravated by BSO treatments (Satoh et al., 
2000, Zhang and Lu, 2007). As an analogue of cisplatin, NDP is less potent than cisplatin in 
generating nephrotoxicity at concentrations where both agents display equivalent anticancer 
activity, whereas the dose-limiting toxicity of NDP is myelosuppression, in 
particular thrombocytopenia (Desoize and Madoulet, 2002, Kawai et al., 2005, Ogawa, 
1996, Sasaki et al., 1991, Vermorken, 2001). A recent study indicated that BSO and TrxR 
inhibitor auranofin potentiate 17-allylamino-17-demethoxygeldanamycin induced cancer cell 
killing (Scarbrough et al., 2012), and mice treated simultaneously with BSO and auranofin 
showed no alterations in circulating leukocytes or red blood cells (Fath et al., 2011), thus 
suggesting that the combination of TrxR and GSH does not aggravate myelosuppression. 
Consistent with this conclusion, the present study demonstrates that the combination of NDP and 
BSO does not generate significant hematological toxicity (Fig. 6E). TrxR inhibition is known to 
largely underlie ifosfamide- or cisplatin-generated nephrotoxicity (Zhang and Lu, 2007, Zhang et 
al., 2008); herein, we have shown that NDP at the pharmacological level used does not inhibit 
renal TrxR activity (Fig. 6A); accordingly, renal tissues were not subjected to the simultaneous 
modulation of TrxR and GSH (Figs. 6A, B), and as a result, renal structures as well as plasma 
BUN and Cr all remained normal (Figs. 6D, E), which is consistent with the observation that 
NDP-induced growth suppression was not enhanced by BSO (Fig. 6C). 
 
In conclusion, the present study has revealed that the anticancer mechanism of NDP involves 
TrxR inhibition, and that as an adaptive response to this inhibition, the viable ascitic cancer cells 
after NDP treatment enlarge themselves to expand their intracellular antioxidant arsenal. 
Furthermore, BSO is a powerful agent that can eliminate this GSH-dependent adaptive response 
and thus enhance the therapeutic efficacy of NDP. 
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Supplementary Fig. 1. Effects of NDP on TrxR expression in ascitic H22 cells. Mice  
were i.p. injected with saline or 25 mg/kg NDP at 72 h after H22 cells were inoculated, 
then sacrificed at 144 h. mRNA levels were analyzed by real-time PCR, followed the 
instructions of the RT-PCR PrimerScript RT reagent Kit (TaKaRa) using the Bio-Rad 
CFX Manager Detection System, Forward primer of TrxR1: 
5'-ACCTGGGCATCCCTGGAGAC-3'. Reverse primer of TrxR1: 
5'-GCACCATTACAGTGACGTCTAAGC-3'. Forward primer of Beta-actin: 
5'-GCTGAGAGGGAAATCGTGCGT-3'. Reverse primer of Beta-actin: 
5'-ACCGCTCGTTGCCAATAGTGA-3'. RT-PCR conditions: 95℃ for 30s, then 35 
cycles at 95℃ for 5 s，56℃ for  30 s and 72℃ for 30 s. Data were shown as 
relative to equivalent amounts of cells. (A) Cellular morphology (×200). Cells were 
observed under an optical microscope. (B) mRNA levels of TrxR1. (C) mRNA levels 
of Beta-actin. (D) Total RNA levels. Data in B, C and D are expressed as mean ± 
SEM (n = 6). (E) Western blot analysis of TrxR1. TrxR1 antibody was purchased from 
Santa Cruz. Protein extracts were prepared from ascitic H22 cells; representative 
results of three independent experiments are shown. Coomassie blue staining is shown 
in the bottom panel.  
 
A
    
B
   
C
   
D
   
E
     
    
Control NDP30 NDP100
0.0
2.5
5.0
7.5
10.0
12.5
15.0
Tr
xR
 a
ct
iv
it
y 
(m
U
/m
g 
Pr
o.
)
      
Control BSO50 BSO150 BSO250
0.0
0.5
1.0
1.5
2.0
N
PF
T 
(n
m
ol
/m
g 
pr
o.
)
 
Control NDP30 NDP100
0
50
100
150
Pe
rc
en
ta
ge
 c
el
l v
ia
bi
lit
y
       
Control BSO250 NDP30 NDP30 / BSO250
0
50
100
150
Pe
rc
en
ta
ge
 c
el
l v
ia
bi
lit
y
 
Supplementary Fig. 2. Impact of BSO on the effect of NDP in oral squamous cell 
carcinoma Tca8113 in vitro. Tca8113 Cells purchased from Cell Bank of the Chinese 
Academy of Sciences were cultured in RPMI1640 media containing 10% fetal calf 
serum (Hyclone), incubated at 37ºC, 5% CO2 for 72 h, and cells were treated with 
NDP (µg/ml) or NDP plus BSO (µM). Viable cell number was determined as 
described in materials and methods. (A) Dose effect of NDP on TrxR activity at 6 h. 
(B) Dose effect of NDP on NPFT levels at 6 h. (C) Cytotoxic effect of NDP at 18 h. 
(D) Cytotoxic effect of NDP or BSO alone and NDP plus BSO at 18 h. Data in B, C 
and D are expressed as mean ± SEM (n = 3). 
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